Compare · EFTR vs NVO
EFTR vs NVO
Side-by-side comparison of eFFECTOR Therapeutics Inc. (EFTR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EFTR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 817.2x EFTR ($229.5M).
- Over the past year, EFTR is up 0.0% and NVO is down 38.9% - EFTR leads by 38.9 points.
- NVO has hit the wire 11 times in the past 4 weeks while EFTR has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 9 for EFTR).
- Company
- eFFECTOR Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $0.19-26.76%
- $43.98+4.69%
- Market cap
- $229.5M
- $187.53B
- 1M return
- +0.00%
- -1.95%
- 1Y return
- +0.00%
- -38.89%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 11
- Recent ratings
- 9
- 25
eFFECTOR Therapeutics Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EFTR
- SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.
- SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.
- SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.
- SEC Form EFFECT filed by eFFECTOR Therapeutics Inc.
- SEC Form 15-12G filed by eFFECTOR Therapeutics Inc.
- SEC Form S-8 POS filed by eFFECTOR Therapeutics Inc.
- SEC Form S-8 POS filed by eFFECTOR Therapeutics Inc.
- SEC Form POS AM filed by eFFECTOR Therapeutics Inc.
- SEC Form POS AM filed by eFFECTOR Therapeutics Inc.
- SEC Form POS AM filed by eFFECTOR Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates